Vanda announces positive results in second Phase III study of Tasimelteon Vanda Pharmaceuticals announced positive results for the second Phase III study of tasimelteon for the treatment of Non-24-Hour Disorder. The Randomized-withdrawal study of the Efficacy and Safety of Tasimelteon to treat Non-24-Hour Disorder, or RESET study, demonstrated the maintenance effect of 20mg of tasimelteon to entrain melatonin and cortisol circadian rhythms in individuals with Non-24. Tasimelteon treated patients maintained their clinical benefits while placebo treated patients showed significant deterioration in measures of nighttime sleep, daytime naps, and timing of sleep. Non-24 is a serious, rare circadian rhythm disorder that affects a majority of totally blind individuals who lack light perception and cannot entrain their master body clock to the 24-hour day. Currently there is no approved treatment for Non-24.
News For VNDA From The Last 14 Days
Check below for free stories on VNDA the last two weeks.
Subscribe for More Information
